Last reviewed 2026-04-19 · How we verify

TRX518 with nivolumab

Leap Therapeutics, Inc. · Phase 1 active Small molecule

TRX518 with nivolumab is a Small molecule drug developed by Leap Therapeutics, Inc.. It is currently in Phase 1 development.

At a glance

Generic name	TRX518 with nivolumab
Sponsor	Leap Therapeutics, Inc.
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Phase 1 Open-label Study of TRX518 Monotherapy and TRX518 in Combination With Gemcitabine, Pembrolizumab, or Nivolumab (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

TRX518 with nivolumab CI brief — competitive landscape report
TRX518 with nivolumab updates RSS · CI watch RSS
Leap Therapeutics, Inc. portfolio CI

Frequently asked questions about TRX518 with nivolumab

What is TRX518 with nivolumab?

TRX518 with nivolumab is a Small molecule drug developed by Leap Therapeutics, Inc..

Who makes TRX518 with nivolumab?

TRX518 with nivolumab is developed by Leap Therapeutics, Inc. (see full Leap Therapeutics, Inc. pipeline at /company/leap-therapeutics-inc).

What development phase is TRX518 with nivolumab in?

TRX518 with nivolumab is in Phase 1.

Manufacturer: Leap Therapeutics, Inc. — full pipeline
Compare: TRX518 with nivolumab vs similar drugs
Pricing: TRX518 with nivolumab cost, discount & access